Evogene
EVGN
38 hedge funds and large institutions have $16.7M invested in Evogene in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 20 reducing their positions, and 7 closing their positions.
0.27% less ownership
Funds ownership: 1.82% → 1.55% (-0.27%)
10% less funds holding
Funds holding: 42 → 38 (-4)
31% less capital invested
Capital invested by funds: $24M → $16.7M (-$7.37M)
47% less call options, than puts
Call options by funds: $238K | Put options by funds: $449K
55% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 20
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$494K |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$138K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$94.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$64.6K |
| 5 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
+$42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.3M |
| 2 |
SM
Senvest Management
New York
|
-$656K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$479K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$329K |
| 5 |
PP
PDT Partners
New York
|
-$259K |
EVGN Hedge Fund Activity: Q3 2021 in Review
38 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2021, worth a combined $16.7M — down 31% from $24M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVGN and 3 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $494K. The largest seller was Morgan Stanley, cutting an estimated $1.3M.
- 38 institutional investors held Evogene (EVGN) as of Q3 2021, down from 42 in Q2 2021.
- Funds reported $16.7M of Evogene stock for Q3 2021, down 31% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q3 2021 and 7 closed out, a net change of -4 holders.
- The largest Evogene buyer in Q3 2021 was Renaissance Technologies, an estimated $494K added.
- The largest Evogene seller in Q3 2021 was Morgan Stanley, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2021.